Excess Cardiovascular Mortality Among Black Americans 2000-2022.

Competing Interests: Funding Support and Author Disclosures Dr Lu has received research grants from the U.S. National Institutes of Health, the Patient-Centered Outcomes Research Institute, and the Sentara Research Foundation outside of the submitted work. Dr Caraballo was supported by a grant from the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI) (U01FD005938). Dr Khera is an Associate Editor of JAMA; has received support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under awards R01HL167858 and K23HL153775) and the Doris Duke Charitable Foundation (under award 2022060); has received research support, through Yale, from Bristol Myers Squibb, Novo Nordisk, and BridgeBio; is a coinventor of U.S. Pending Patent Applications 63/562,335, 63/177,117, 63/428,569, 63/346,610, 63/484,426, 63/508,315, and 63/606,203; and is a cofounder of Ensight-AI Inc and Evidence2Health, health platforms to improve cardiovascular diagnosis and evidence-based cardiovascular care. Dr Krumholz has received options for Element Science and Identifeye and payments from F-Prime for advisory roles (in the past 3 years); is a cofounder of and holds equity in Hugo Health, Refactor Health, and Ensight-AI; and is associated with research contracts through Yale University from Johnson and Johnson, Kenvue, Novartis, and Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.